Sinovac Biotech Ltd. Filed Its Annual Report on Form 20-F for 2009

BEIJING, April 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. , a leading China-based vaccine manufacturer, announced today it filed its annual report on Form 20-F for the fiscal year ended December 31, 2009 with the Securities and Exchange Commission on April 16, 2010. The annual report on Form 20-F can be accessed on Sinovac's website at http://www.sinovac.com/Investors/SECFilings/ . Sinovac will provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (seasonal influenza), Panflu(TM) (pandemic influenza (H5N1)), and Panflu.1(TM) (pandemic influenza A (H1N1)). Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, pneumococcal infection, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

CONTACT: Helen G. Yang, Sinovac Biotech Ltd., +86-10-8289-0088 x9871, or
fax, +86-10-6296-6910, or info@sinovac.com; Or Investors: Amy
Glynn/Stephanie Carrington of The Ruth Group, +1-646-536-7023/7017, or
aglynn@theruthgroup.com scarrington@theruthgroup.com; Or Media, Janine
McCargo of The Ruth Group, +1-656-536-7033, or jmccargo@theruthgroup.com

Web site: http://www.sinovac.com/